MOREPEN LABS share price has zoomed 8% and is presently trading at Rs 85.0.
Meanwhile, the BSE HEALTHCARE index is at 44,196.0 (up 1.2%).
Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 3.8%) and APOLLO HOSPITALS (up 3.3%).
Jubilant Pharmova (down 2.4%) and GSK Pharma (down 1.7%) are among the top losers today.
Over the last one year, MOREPEN LABS has moved up from Rs 46.4 to Rs 85.0, registering a gain of Rs 38.6 (up 83.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 29,654.9 to 44,196.0, registering a gain of 49.0% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 178.5%), SUVEN PHARMACEUTICALS (up 103.6%) and Glenmark Pharma (up 101.2%).
End of Year Sale: Save Rs 6,050 on our small cap research
The BSE Sensex is at 80,248.1 (up 0.6%).
The top gainers among the BSE Sensex today are Ultratech Cement (up 3.9%) and JSW Steel (up 2.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,275.3 (up 0.6%). Ultratech Cement and APOLLO HOSPITALS are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 66,174.2 to 80,248.1, registering a gain of 14,073.9 points (up 21.3%).
MOREPEN LABS net profit grew 63.9% YoY to Rs 348 million for the quarter ended September 2024, compared to a profit of Rs 213 million a year ago. Net sales rose 3.8% to Rs 4,377 million during the period as against Rs 4,218 million in July-September 2023.
For the year ended March 2024, MOREPEN LABS reported 149.8% increase in net profit to Rs 966 million compared to net profit of Rs 387 million during FY23. Revenue of the company grew 19.3% to Rs 16,904 million during FY24.
The current Price to earnings ratio of MOREPEN LABS, based on rolling 12 month earnings, stands at 35.4.
Equitymaster requests your view! Post a comment on "MOREPEN LABS Gains 8%; BSE HEALTHCARE Index Up 1.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!